Medication Guide App

Tigecycline Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Intraabdominal Infection

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 5 to 14 days

Approved indication: For the treatment of complicated intraabdominal infections due to susceptible isolates of Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus group (includes S anginosus, S intermedius, and S constellatus), Bacteroides fragilis, B thetaiotaomicron, B uniformis, B vulgatus, Clostridium perfringens, and Peptostreptococcus micros

Usual Adult Dose for Skin or Soft Tissue Infection

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 5 to 14 days

Comments:
-Tigecycline is not for the treatment of diabetic foot infections; clinical trial failed to show its non-inferiority.

Approved indication: For the treatment of complicated skin and skin structure infections due to susceptible isolates of E coli, E faecalis (vancomycin-susceptible isolates), S aureus (methicillin-susceptible and -resistant isolates), S agalactiae, S anginosus group (includes S anginosus, S intermedius, and S constellatus), S pyogenes, E cloacae, K pneumoniae, and B fragilis

Usual Adult Dose for Skin and Structure Infection

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 5 to 14 days

Comments:
-Tigecycline is not for the treatment of diabetic foot infections; clinical trial failed to show its non-inferiority.

Approved indication: For the treatment of complicated skin and skin structure infections due to susceptible isolates of E coli, E faecalis (vancomycin-susceptible isolates), S aureus (methicillin-susceptible and -resistant isolates), S agalactiae, S anginosus group (includes S anginosus, S intermedius, and S constellatus), S pyogenes, E cloacae, K pneumoniae, and B fragilis

Usual Adult Dose for Pneumonia

100 mg IV initial dose, followed by 50 mg IV every 12 hours
Duration of therapy: 7 to 14 days

Comments:
-Tigecycline is not for the treatment of hospital-acquired or ventilator-associated pneumonia; greater mortality and decreased efficacy reported in comparative clinical trial.

Approved indication: For the treatment of community-acquired bacterial pneumonia due to susceptible isolates of S pneumoniae (penicillin-susceptible isolates), including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates), and Legionella pneumophila

Usual Pediatric Dose for Intraabdominal Infection

Proposed for complicated infections:
8 to 11 years: 1.2 mg/kg IV every 12 hours
Maximum dose: 50 mg/dose

12 to 17 years: 50 mg IV every 12 hours

Comments:
-Tigecycline should not be used unless no alternative antibacterial agents are available.
-Safety and efficacy of the suggested regimens have not been evaluated due to the increase in mortality observed in tigecycline-treated adult patients.
-Proposed doses based on exposures seen in pharmacokinetic trials (small numbers of pediatric patients included).

Usual Pediatric Dose for Skin and Structure Infection

Proposed for complicated infections:
8 to 11 years: 1.2 mg/kg IV every 12 hours
Maximum dose: 50 mg/dose

12 to 17 years: 50 mg IV every 12 hours

Comments:
-Tigecycline should not be used unless no alternative antibacterial agents are available.
-Safety and efficacy of the suggested regimens have not been evaluated due to the increase in mortality observed in tigecycline-treated adult patients.
-Proposed doses based on exposures seen in pharmacokinetic trials (small numbers of pediatric patients included).

Usual Pediatric Dose for Pneumonia

Proposed for community-acquired bacterial pneumonia:
8 to 11 years: 1.2 mg/kg IV every 12 hours
Maximum dose: 50 mg/dose

12 to 17 years: 50 mg IV every 12 hours

Comments:
-Tigecycline should not be used unless no alternative antibacterial agents are available.
-Safety and efficacy of the suggested regimens have not been evaluated due to the increase in mortality observed in tigecycline-treated adult patients.
-Proposed doses based on exposures seen in pharmacokinetic trials (small numbers of pediatric patients included).

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A and B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): 100 mg IV initial dose, followed by 25 mg IV every 12 hours; caution recommended

Precautions

Consult WARNINGS section for dosing related precautions.

Dialysis

Hemodialysis: No adjustment recommended.
Peritoneal dialysis: Data not available

Other Comments

Administration advice:
-Reserve tigecycline for situations when alternative therapies are not suitable.
-Duration of therapy should be guided by the severity and site of the infection and clinical and bacteriological progress of the patient.
-Administer IV infusions over 30 to 60 minutes through a dedicated line or through a Y-site.
-If same IV line used for sequential infusion of several drugs, flush the line before and after tigecycline infusion; the manufacturer's product information should be consulted.

Storage requirements:
-Prior to reconstitution: Should be stored at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F)
-After reconstitution: Tigecycline may be stored at room temperature (not to exceed 25C [77F]) for up to 24 hours (up to 6 hours in the vial and the remaining time in the IV bag); if storage conditions exceed 25C (77F), tigecycline should be used immediately. Alternatively, tigecycline mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2C to 8C (36F to 46F) for up to 48 hours after immediate transfer of reconstituted solution into the IV bag.

Reconstitution/preparation techniques:
-The manufacturer's product information should be consulted.

IV compatibility:
-Compatible IV solutions: 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, Lactated Ringer's Injection, USP
-Compatible drugs/diluents (when used with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP): Amikacin, dobutamine, dopamine hydrochloride (HCl), gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin-tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, tobramycin
-Incompatible drugs: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole

General:
-Appropriate specimens should be obtained for bacteriological examination to isolate and identify causative organisms and determine susceptibility to tigecycline; may start tigecycline as empiric monotherapy before test results are known.
-Each vial contains 100 mg lactose monohydrate.

Monitoring:
-General: For superinfection (during therapy); treatment response in patients with severe liver dysfunction
-Hepatic: For worsening hepatic function in patients who develop abnormal liver function tests during therapy

Hide
(web2)